Epidemiology shows a clear correlation between chronic infection with the hepatitis B virus (HBV) and development of hepatocellular carcinoma (HCC). The potential role of the transactivating hepatitis B virus X protein (HBx) in transformation by HBV is controversial. Here we report that HBx suppresses transformation of primary rat embryo ®broblasts (REFs). Cooperating oncogenes like c-Ha-ras and c-myc transform REF very eciently but cotransfection with HBx suppressed transformation of REFs down to 5%. Similarly, transfection of HBx together with the cooperating oncogenes Ha-ras and SV40 LTAg or c-Ha-ras and mutant p53 reduced the number of foci to 13%. Comparable results were obtained with HBx in the context of the whole HBV. Suppression of focus formation in REF could be partly relieved by cotransfection of apoptosis inhibitors Bcl-2 or E1B. However, cotransfection of apoptosis inhibitors crmA and p35 did not in¯uence the proapoptotic functions of HBx. Thus, HBx may speci®cally activate the Bcl-2 sensitive pathway leading to apoptosis. Experiments with 13 HBx linker scanning mutants revealed that the domains necessary for HBx dependent transactivation overlap with the domains needed for the apoptotic/growth arrest functions of HBx.
Introduction
Epidemiological data show a clear correlation between chronic HBV infection and the development of HCC (for reviews see BreÂ chot et al. (1998) ). However, the molecular mechanism of transformation by HBV is unsolved. Several groups have demonstrated an oncogenic potential of HBV DNA in a wide range of experimental systems (for review: Schaefer (1999) ; Schaefer and Gerlich (1995) ). Stable expression of a small viral protein, HBx, showed a weak ± but reproducible ± transforming eect of HBx in cell lines of liver origin (Oguey et al., 1996; Schaefer et al., 1998; Seifer et al., 1991a; Tarn et al., 1999) , in murine ®broblasts (Seifer et al., 1991b; Shirakata et al., 1989) and in rat ®broblasts (Gottlob et al., 1998b ) (for review: Schaefer (1999) ; Schaefer and Gerlich (1995) ).
The function of HBx for HBV replication is not understood. While HBx is dispensable for replication in vitro (Blum et al., 1992) , HBx is essential for establishment of infection in the woodchuck (Marmota monax) by the closely related woodchuck hepatitis virus (WHV) Zoulim et al., 1994) . A plethora of in vitro activities and interactions with cellular partners by HBx have been reported (for review: Yen (1996) ). HBx indiscriminately transactivates many viral and cellular promoters and enhancers, among them the promoters for the cellular protooncogenes c-myc (KekuleÂ et al., 1993) , c-fos (Avantaggiati et al., 1993) and c-jun (Twu et al., 1993) . Transactivation by HBx is mainly exerted via activation of cytoplasmic signaling cascades (Doria et al., 1995; Natoli et al., 1994) , the eect of HBx on the RasRaf-MAP kinase pathway being the best studied: this signaling pathway has been found to be activated at the level of Ras (Doria et al., 1995) or even further upstream by Src (Klein and . However, transactivation by HBx might also be transferred by signal cascades dierent from Ras-Raf (KekuleÂ et al., 1993; Lara-Pezzi et al., 1998; Lee and Yun, 1998) .
In primary hepatocytes of murine (Wang et al., 1995) and human (Elmore et al., 1997) origin expression of HBx prevented apoptosis induced by microinjection of p53. However, in stable cell lines transient expression of HBx enhanced or enabled induction of apoptosis by several stimuli (Chirillo et al., 1997; Kim et al., 1998; Su and Schneider, 1997; Terradillos et al., 1998) .
In order to analyse the oncogenic properties of HBx we employed rat embryo ®broblasts (REF) which can be transformed by transfection with two cooperating oncogenes (Land et al., 1983) . Cotransfection of HBx with various single oncogenes did not transform REF.
Quite in contrast, cotransfection of HBx together with pairs of cooperating oncogenes drastically suppressed formation of transformed foci. This new activity could be relieved partially by inhibitors of apoptosis.
Results

HBx suppresses focus formation by cooperating oncogenes
In order to measure the presumed oncogenic potential of HBx we cotransfected HBx expression vectors together with c-H-ras, c-myc, mutant p53 or SV40TAg. Neither of these combinations produced foci in numbers above back ground level in REFs (see Table  1 ). Because transformation of the stable hepatocyte line FMH202 by the whole HBV genome had been found to be much more eective than transformation by HBx expression vectors alone (Schaefer and Gerlich, 1995) , we tried to transform REF by a replication competent HBV construct. However, no transformation of REF could be observed using the whole HBV genome and dierent complementing oncogenes (Table 1) .
HBV and HBx are assumed to be only weak oncogenes in vitro. A transforming eect of weak oncogenes can be investigated in REF by triple transfections together with a pair of complementing oncogenes (Parker et al., 1996; Peacock et al., 1990) . Thus, we cotransfected HBx along with Ras and SV40TAg ( Figure 1 and Table 2 ). However, in contrast to our expectations, HBx was found to have a strong suppressive eect on focus formation. This suppression was dependent on HBx protein because a control vector with two stop codons (pCXm) did not signi®cantly suppress focus formation. Expression of HBx protein from wt-HBx expression constructs had been controlled by immune¯uorescence (data not shown). HBx expressed from the CMV enhancer (pCX) had a stronger eect than HBx constructs using the uninduced metallothionein promoter (pMX). Northern blots showed that expression of HBx RNA is much stronger from the CMV enhancer than from the metallothionein enhancer (Figure 2) .
Because an antagonism between HBx and SV40TAg in transactivation has been reported (Doria et al., 1995; Spandau and Lee, 1988) we wanted to rule out that inhibition of transformation by Ras/SV40TAg was due to a speci®c HBx-SV40TAg antagonism. Therefore we investigated the eect of HBx on transformation by two additional pairs of oncogenes. However, HBx also suppressed transformation of REF by Ras/myc and Ras/mutant p53 (Figure 3) .
Suppression of focus formation in the REF system so far has been described for few proteins only, among them the tumor suppressor p53 (Finlay et al., 1989) and recently the cyclin kinase inhibitor p21 sdi/waf/cip (Haas et al., 1997) . To compare the focus suppressive eect of these bona ®de tumor suppressors/cell cycle inhibitors with that of HBx, we tested expression constructs of human wt p53 and rat p21 sdi/waf/cip for their focus suppressive activity in our system. Figure 4 shows that p53 has a lower suppressive activity of about 38% in comparison to HBx which suppressed focus formation to 19%. In this set of experiments p21 reduced the number of foci more eciently to about 6% (Figure 4 ).
Counter selection against HBx in cell clones
In all experiments, HBx never suppressed 100% of focus formation. Thus, we analysed whether these residual transformed foci were due to loss of HBx expression or failure of triple transfection, i.e. that only expression vectors for the cooperating oncogenes were taken up by the transfected single cell and for statistical reasons HBx was absent. For this purpose 22 G418-resistant colonies, visible 14d post transfection with Ras/SV40TAg/wt HBx or defective HBx were picked and propagated until harvested for RNA extraction. Figure 5 shows that in 10/10 cells picked from foci obtained after cotransfection with protein expression negative pCXm, uniform bands of HBx message ampli®ed by RT ± PCR were visible. However, in 5/12 wt-HBx transfected clones no or only barely visible HBx speci®c message could be ampli®ed in 35 cycles of PCR and in further six clones, expression of HBx RNA was much lower than in pCXm-transfected cells. The mechanism of the high expression of HBx-RNA in clone 11 is not known. However, spontaneous mutations of HBx or transfection of cells resistant to HBx induced apoptosis could have led to these results. Focus formation appears to be possible only in cells where HBx expression is downregulated by unknown mechanisms.
Focus suppressive activity of HBx is dose dependent
As we noted that HBx expressed from the strong CMV promoter reduced focus formation by Ras/SV40TAg more than HBx expressed from the weak uninduced metallothionein promoter ( Figure 2 ) we analysed whether the HBx activity to suppress focus formation in REF by complementing oncogenes is dose dependent. Using construct pMX where HBx expression is driven by the weak uninduced metallothionein promoter a clear dose dependency could be shown. At 1 mg of HBx expression construct, focus formation was reduced to about 50% ( Figure 6 ). Suppression of focus formation increased to about 10% at 10 mg pMX ( Figure 6 ). Cotransfection of a transactivation negative HBx mutant had no eect on focus formation even at 10 mg cotransfected vector. 
Suppression of focus formation depends on transactivator activity of HBx
We investigated whether HBx' ability to suppress focus formation depends on transcriptional activation by HBx or is a new independent activity of HBx that can be dissected from domains of HBx protein necessary for transactivation. To analyse the complete length of HBx protein for its focus suppressive activity we used linker scanning mutants of HBx (Figure 7a ) generated and characterized by (Runkel et al., 1993) . All mutants were cotransfected with the cooperating oncogenes cHa-ras and c-myc. Figure 7b shows that HBx domains necessary for transcriptional activation overlap inseparable with the domains needed for proapoptotic activity. No mutant could be found which showed discrepant results in transactivation compared to suppression of focus formation. Only mutant M10 initially appeared to diverge. However, retesting of several mutants for transactivation competence in rodent ®broblasts (Swiss3T3) showed that the results of (Runkel et al., 1993) were largely con®rmed, but HBx mutant M10 transactivated only to 48% and not to about 80% as initially reported. Thus, in our hands the relative activity of M10 to wt-HBx in transactivation and focus suppressive activity is about equal.
Apoptosis inhibitors partially relieve suppression of focus formation by HBx
Recently, HBx was shown to induce or enhance apoptosis in diverse cell lines of mammalian origin (Chirillo et al., 1997; Kim et al., 1998; Su and Schneider, 1997; Terradillos et al., 1998) . We therefore tested whether the HBx activities observed in REF Figure 7 HBx domains needed for transactivation overlap with the domains necessary for proapoptotic activity. (a) The numbers in the HBx-ORF indicate the position where a linker (Arg-Pro) was inserted to produce HBx linker scanning mutants (Runkel et al., 1993) . Above the triangles the designation of the respective HBx-mutant is given. The black box indicates the minimal length of the HBx protein retaining transactivation activity. (b) Open bars represent transcriptional activity of mutants M1 to M15 relative to wtHBx (pMX) as reported by (Runkel et al., 1993) Focus suppression by hepatitis B virus X protein R Schuster et al could be reversed by inhibitors of apoptosis signaling cascades. Figure 8 shows that indeed Bcl-2 and E1B expression constructs could partially reverse the suppression of focus formation by HBx. However, apoptosis inhibitors p35 from baculovirus and crmA (cytokine response modi®er A) from cowpox virus failed to relieve the suppressive functions of HBx. Failure of crmA and p35 to counteract the investigated activity of HBx was not due to absence of expression. Both genes were biologically active in this assay and crmA inhibited apoptosis induced by p53 in REF (data not shown). Further intensive eorts to analyse apoptosis induction in primary rat embryo ®broblasts by FACS or several other methods yielded inconclusive results due to the high background of (primary) cells damaged by the transfection procedure itself.
Expression of HBx from the context of the whole genome also suppresses focus formation
Many decades of experience with natural infection by wt-HBV have never given a hint as to cytopathic eects of HBV replication in infected hepatocytes other than those caused by immunological reactions. Thus, we analysed whether expression of constructs competent for HBV replication would abrogate the proapoptotic activities of HBx by expression of an antagonistic viral protein. We cotransfected two dierent HBV constructs along with the cooperating oncogenes c-Ha-ras and c-myc. As a negative control we used identical HBV constructs where HBx expression was rendered impossible due to two stop codons inserted by sitedirected mutagenesis. Both HBV wt-constructs suppressed focus formation as strong as HBx expression from the CMV enhancer ( Figure 9 ). It even appeared as if wt-HBV constructs were more potent in this assay than HBx alone. This raises the possibility that HBV codes for a second viral protein which acts synergistically in suppression of focus formation.
Discussion
The oncogenic potential of HBx has previously been shown in cell lines and certain strains of transgenic mice. Furthermore, HBx gene sequences have more often been found to be integrated in the chromosomes of HBV associated HCCs than other regions of the HBV genome (SchluÈ ter et al., 1994) . In order to verify the transforming capacity of HBx in vitro we used the well established system of focus formation in REF.
It was not too surprising that in this demanding system HBx could not complement other better established oncogenes neither by itself nor in the context of the entire genome. More surprising was the observation that HBx both by itself and in the HBV genome context even suppressed the focus formation. The eect was dependent on the dose of HBx and required either a strong enhancer/promoter like the one from the immediate early genes of CMV or a high dose of transfected expression vector. This observation may explain the seeming contradiction to previous reports on HBx induced transformation of immortalized murine hepatocyte lines (HoÈ hne et al., 1990; Oguey et al., 1996; Seifer et al., 1991a; Tarn et al., 1999) and of murine (Seifer et al., 1991b; Shirakata et al., 1989) and rat ®broblast lines (Gottlob et al., 1998b) . In these studies stably transfected cell clones were ®rst selected by G418 resistance and then assayed for transformation by colony formation or tumor growth in nude mice. Under such conditions, HBx expression is downregulated (Oguey et al., 1996 ; and references therein), probably because full expression of HBx would induce apoptosis or cell cycle arrest. The few HBx transfected colonies which grew out in our study expressed much less HBx-RNA than control colonies which expressed an inactive HBx-gene. It appears that low level expression of HBx supports transformation in immortalized cell lines but is not sucient in primary cells like REFs where it could not complement single oncogenes. DNA tumor viruses like adenoviruses code for at least two genes needed for transformation. E1A of adenovirus 5 drives cells into active cell cycle but has an inherent apoptotic activity which must be relieved by E1B of adenovirus, a strong inhibitor of apoptosis (White et al., 1991) , in order to obtain transformation. Thus, one could speculate if the genome of HBV might also code for a viral protein with the ability to antagonize HBx' focus suppressing activity. However, cotransfection of two dierent replication competent HBV constructs suppressed focus formation in REF at least as much as HBx alone (Figure 9 ), whereas isogenic HBx expression-negative mutants diering only by two nucleotides did not show such a strong eect. These data imply that under the conditions used, no viral protein is expressed in REF that can antagonize HBx' focus suppressing activity. This experiment showed furthermore that functional HBx can be expressed from constructs containing only HBV speci®c transcriptional elements in nonhepatic cells like REF. Although HBV is a hepatotropic virus, replication, production of viral particles (Seifer et al., 1990a,b) and even expression of infectious virus (WHV, a related hepadnavirus) (Seeger et al., 1989) has been described in murine ®broblast lines with constructs similar to the ones used in our study. Thus, failure of HBV constructs to relieve focus suppression by HBx in REF was most likely not due to insucient expression of a hypothetical antagonist of HBx' focus suppressive activity.
Several groups consistently showed that HBx can induce or enhance apoptosis (Chirillo et al., 1997; Kim et al., 1998; Su and Schneider, 1997; Terradillos et al., 1998) . Apoptosis induction by HBx could be partially relieved by the inhibitor Bcl-2 (Kim et al., 1998) , E1B or dominant negative c-jun n-terminal kinase (JNK) (Su and . Thus, we analysed whether suppression of focus formation in REF by HBx was also caused by induction of apoptosis. Figure 8 shows that expression vectors for Bcl-2 and E1B signi®cantly reduced HBx' suppressive activity. The magnitude of Bcl-2 and E1B antagonism to the activities of HBx in our system are in the same range as those observed by (Kim et al., 1998; Su and Schneider, 1997) in cell lines of hepatic origin. However, cotransfection of constructs for apoptosis inhibitors p35 and crmA were without eect on focus suppression by HBx, although crmA was able to relieve apoptosis induction by p53 in REF (data not shown). These data could be interpreted in such a way that HBx activates only the Bcl-2 sensitive signaling cascade ultimately leading to apoptosis (Cory and Adams, 1998) . HBx' ability to activate transcription through the Ras-Raf-MAP kinase pathway is well documented (Doria et al., 1995; Natoli et al., 1994) . Like the proapoptotic functions of HBx, the transcriptional activation by HBx could also be inhibited by dominant negative JNK (Benn et al., 1996) . Activation of the Ras-Raf cascade also induces a strong cell cycle arrest in G 1/S by enhanced expression of p21 cip/sdi/waf (Olson et al., 1998) . In this respect it is noteworthy that enhanced expression of p21 cip/sdi/waf by HBx and subsequent G 1/S arrest have been found which could be explained by activation of the Ras-Raf cascade. Hence most activities of HBx, including the eects described here can possibly be attributed to activation of the Ras-Raf cascade. The intracellular integration of signals coming from diverse physiological stimuli of signaling cascades activated by Ras-Raf (Khosravi-Far et al., 1998) decides if a cell enters apoptosis (Chi et al., 1999) or not (Peli et al., 1999) , arrests in G 1/S (Olson et al., 1998) , transactivates diverse cellular promoters or becomes transformed. Thus, synergistic activation of the Ras-Raf signaling cascade by HBx and other stimuli, or signals coming from activation of additional signaling cascades by HBx may trigger all the dierent events seen by Ras-activation. In this respect, it is not surprising that recently, inhibition of apoptosis by stable expression of HBx in a rat ®broblast line has been described (Gottlob et al., 1998a) . The antiapoptotic functions of HBx depended completely on intact transcriptional activation functions of HBx (Gottlob et al., 1998a) .
In our experiments, the proapoptotic activities of HBx were also dependent on transcriptional activation by HBx as shown in Figure 7 . Transactivation and pro-apoptotic functions of HBx were inseparable. In addition, HBx genes from human, ground squirrel, woodchuck or arctic squirrel hepadnaviruses with deletion of the c-terminal Kunitz domain indispensable for transactivation have all lost the ability to induce apoptosis in REF (R Schuster, in preparation) . These results are in agreement with the data of (Bergametti et al., 1999) who found a proapototic eect of stably expressed wt-HBx. However, this eect was not observed in a cell line expressing mutant HBx M7, also used in our study. Thus, our results suggest that HBx induced activation of signaling cascades has an in¯uence on a central growth control mechanism. We postulate that very high expression of HBx activates signaling cascades/eectors downstream of Ras that lead to apoptosis, whereas low expression of HBx ± as observed in stable HBx transfected cell lines ± could activate intracellular pathways that have opposing eects, like transformation.
Another interesting hypothesis for the contribution of HBx in the development HCC would be that in tumors certain mutated forms of HBx are selected which either enable a transforming activity of HBx by loss of apoptotic functions Sirma et al., 1999) or directly contribute to oncogenesis by gain of transforming functions (Kairat et al., 1999; Rakotomahanina et al., 1994) . Interestingly, both kinds of variants found have largely lost transactivational activities (Rakotomahanina et al., 1994; Sirma et al., 1999) . Thus, it appears possible that transactivation and transformation are separable functions of HBx as recently reported (Gottlob et al., 1998b) .
Materials and methods
Cells, transfection and focus assay
Pregnant Fischer rats were obtained from Charles River Laboratories (Sulzberg, Germany). Primary embryo ®bro-blasts from d14 (post conception) embryos were prepared as described by Land (1995) .
For transfection 1.2610 6 REF were transfected by calcium phosphate precipitation (described in Ausubel et al. (1998) ) and thereafter the protocol of Land (1995) was followed. For each experiment the transfections were done in triplicate and 
Northern blot
For Northern blot, total cellular RNA was extracted from REF 48 h post transfection using Trizol (Gibco). 20 mg of DNase1 digested RNA was separated on a glyoxal agarose gel (1% in 10 mM Na 2 HPO 4 ) and blotted onto positively charged nylon membrane. The blot was hybridized with a 32 P-labeled HBx-speci®c probe.
RT ± PCR
For RT ± PCR 2 mg of total cellular RNA extracted with Qiagen RNeasy was digested with DNaseI for 45 min. One mg of DNaseI digested RNA was reverse transcribed with superscript (Gibco). One quarter of the reverse transcribed RNA was ampli®ed with Taq polymerase (1' 948C, 1' 548C, 1' 728C: 635 cycles) using HBx speci®c primers which had been used for cloning the complete HBx ORF into pCDNA3.
Constructs pCX
The complete HBx ORF of an HBV genotype A genome (serotype adw2; isolate 991; EMBL accession no.: X51970) was cloned with the help of PCR into the EcoRI and XbaI-site of pCDNA3, Invitrogen, and controlled by sequencing.
pCXm Identical to pCX except for two stop codons introduced by a G to A exchange of nt 1443 (GAA?TAA) (Seifer et al., 1991a) and a C to A exchange of nt 1684 (TCA?TAA). Thus, translation of full-length HBx is stopped by exchange of nt 1443 after 23 aa and expression of presumed small HBx proteins is made impossible by exchange of nt 1684 which introduces a stop directly after the third start codon in frame in the HBx-ORF.
pBS991dimer T7 EcoRI dimer of the same HBV genome (see pCX) cloned via EcoRI into pBluescriptSKII + .
pCHBV Replication competent pregenome of the same HBV isolate (see above) from nt 1820 ± 3221/1 to nt 1984 was cloned into the CMV-driven expression vector pCDNA3.
pBS991dimer T7Xm and pCHBVXm: Identical to pBS991dimer T7 and pCHBV except for the two codon exchanges at nt 1443 and 1684 described above which inhibit expression of HBx but do not in¯uence replication of HBV in vitro (unpublished results).
pCDNA-p21 Rat p21
sdi/cip/waf was cloned by RT ± PCR. Total cellular RNA from REF was ampli®ed after RT by primers encompassing the start and stop codon of rat p21. The ampli®ed fragment was cloned into the EcoRI-site of pCDNA3. Sequencing and homology search in GenBank revealed identity to rat p21 from (el-Deiry et al., 1995) .
pMX and mutants M1 ± M15 Expression of HBx and mutants is controlled by the human metallothionein IIa promoter. By insertion of two codons (Arg-Pro) 13 mutants have been constructed (Runkel et al., 1993) . All constructs have been cloned in the laboratory of H Schaller and been characterized extensively for protein expression and transactivation activity (Runkel et al., 1993) .
The description of the expression vectors for wt (pC53-SN3) and mutant p53: 143 V?A (pC53-SCX3) (Kern et al., 1992) ; mutant p53: 249 R?S (pC53-249) (Ponchel et al., 1994) ; c-Ha-ras (pEJ-ras) and c-myc (Land et al., 1983) ; SV40-TAg (pCMV-T) (Dimri et al., 1996) ; human Bcl-2 (bcl2-pSFFV-neo) (Cuende et al., 1993) , baculovirus p35 (p35-pSFFV-neo) (Qi et al., 1997) ; adenovirus E1B (pCMVE1B) (White et al., 1991) , and cowpox protein crmA (pHD1.2 crmA) (Susin et al., 1997) has been published. We thank H Schaller (pMX and mutants), B Vogelstein (wt p53 and mutant 143), M O È ztuÈ rk (mutant p53-249), B Luber (cHa-ras and c-myc), J Campisi (SV40TAg), CW Distelhorst (p35 and Bcl-2), E White (E1B) and MA Buendia (crmA) for providing the indicated constructs.
